Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Lakewood-Amedex Biotherapeutics Inc. (LABT) had Consolidated Net Income/Loss of $-3.85M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-5.85M |
|
-- |
|
-- |
|
$3.77M |
|
$-3.77M |
|
$-0.08M |
|
$-3.85M |
|
$-3.85M |
|
$-3.85M |
|
$-3.85M |
|
|
Consolidated Net Income/Loss |
$-3.85M |
$-3.85M |
|
$-3.77M |
|
$-3.65M |
|
0.70M |
|
0.70M |
|
$-8.40 |
|
$-8.40 |
|
| Balance Sheet Financials | |
$0.31M |
|
$0.01M |
|
$0.18M |
|
$0.48M |
|
$2.41M |
|
-- |
|
$0.04M |
|
$2.45M |
|
$-1.97M |
|
$-1.96M |
|
$-1.96M |
|
0.70M |
|
| Cash Flow Statement Financials | |
$-1.94M |
|
-- |
|
$1.50M |
|
$0.68M |
|
$0.24M |
|
$-0.44M |
|
$1.35M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.13 |
|
-- |
|
-- |
|
-- |
|
-0.76 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.94M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
195.55% |
|
195.85% |
|
-798.93% |
|
195.85% |
|
$-2.81 |
|
$-2.79 |
|
$-2.79 |
|